Sold as Mefloquine Hydrochloride, Lariam. Every FDA application for this active ingredient: 2 branded and 4 generic.
As of Nov 16, 2026, FDA lists 6 applications for Mefloquine Hydrochloride (sold as Mefloquine Hydrochloride, Lariam), first approved May 2, 1989, with 1 new use approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Mefloquine HCl | Part D | $337K | -16% | 7,046 |
| May 2, 1989 | Mefloquine HydrochlorideNDA 19578 · New molecular entity | US Army Walter Reed | 0 | Discontinued |
| May 2, 1989 | LariamNDA 19591 · New formulation or manufacturer | Roche | 27 | Discontinued |
| Feb 20, 2002 | Mefloquine HydrochlorideANDA 76175 | Chartwell Rx | 9 | Marketed |
| Dec 29, 2003 | Mefloquine HydrochlorideANDA 76392 | Barr | 5 | Marketed |
| Oct 1, 2004 | Mefloquine HydrochlorideANDA 76523 | Hikma | 7 | Discontinued |
| Apr 21, 2010 | Mefloquine HydrochlorideANDA 77699 | Hikma Intl Pharms | 3 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA